Skip to main content
You are the owner of this article.
You have permission to edit this article.
Zoetis doing another expansion in Lincoln
editor's pick alert top story

Zoetis doing another expansion in Lincoln

  • Updated
  • 0
Zoetris Expansion, 7.22

Work continues on a three-story addition on the east side of the Zoetis plant at 601 W. Cornhusker Highway.

Growth in demand for immunotherapy treatments for pets is leading to another expansion at Zoetis in Lincoln.

A three-story addition currently under construction on the east side of the plant at 601 W. Cornhusker Highway will house space for production as well as research and development for monoclonal antibody drugs.

Monoclonal antibodies, which are proteins made in a laboratory that mimic the body's immune response, came into the spotlight last year as a potential treatment for COVID-19 infections, but they've been used for years for treating cancer and autoimmune diseases such as rheumatoid arthritis.

Kawasaki to expand in Lincoln, add hundreds of jobs

Zoetis currently makes two monoclonal antibody drugs for dogs in Lincoln — Cytopoint, a skin treatment, and Librela, a treatment for arthritis.

Cytopoint has been licensed for use in the U.S. since 2016, and the company mentioned its importance in driving a 36% year-over-year increase in first-quarter sales in its companion animal segment.

Librela is a much newer drug that was approved for use in Europe just last fall. Approval in the U.S. is still pending.

Exclusive: Google appears to be company behind Lincoln data center

"The company's making the investment to be able to make more" of those products, said Chris Rasmussen, who has been general manager of the Lincoln Zoetis plant since January.

Rasmussen declined to give the size or cost of the expansion, citing competitive reasons, but said it should be completed sometime in 2023.

He said this will be the fifth expansion of the plant in the past six years, a sign of how important the Lincoln site is to Zoetis' ongoing plans.

Lincoln company shows off its latest mobile COVID-19 unit as new cases tick up in Nebraska

Zoetis, which was spun off as a separate company from Pfizer in 2013, has spent more than $100 million to add space at the Lincoln plant for the production of both livestock and companion animal vaccines. In fact, a 2016 expansion on the west side of the plant facilitated the initial production of Cytopoint.

Those physical expansions have brought with them the need for more workers, too. When it was spun off as its own company eight years ago, Zoetis had about 550 employees in Lincoln. Rasmussen said that number is now more than 700, and the latest expansion will result in the addition of another 20 to 40 positions.

"I'm really excited about it," he said.

With NRD well approval, Monolith Materials set to start on expansion south of Lincoln

Reach the writer at 402-473-2647 or

On Twitter @LincolnBizBuzz.


The business news you need

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Business reporter

Matt Olberding is a Lincoln native and University of Nebraska-Lincoln graduate who has been covering business for the Journal Star since 2005.

Related to this story

Get up-to-the-minute news sent straight to your device.


News Alerts

Breaking News

Husker News